Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen in prostatic carcinoma.

C D Jurincic1, H U Pixberg, A Gasser

  • 1Department of Urology, General Hospital Celle, FRG.

Urologia Internationalis
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biology of soft tissue repair: gingival epithelium in wound healing and attachment to the tooth and abutment surface.

European cells & materials·2019
Same author

Fibroblast Growth Factor 23 drives MMP13 expression in human osteoarthritic chondrocytes in a Klotho-independent manner.

Osteoarthritis and cartilage·2016
Same author

Record of two species of Culicoides (Diptera, Ceratopogonidae) new for Madagascar and molecular study showing the paraphylies of the subgenus Oecacta and the Schultzei group.

Bulletin de la Societe de pathologie exotique (1990)·2013
Same author

[Medizinische Klinik - Intensivmedizin und Notfallmedizin].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2011
Same author

Transient hyperglycaemia in a prediabetic dog treated with prednisone and cyclosporin A.

Australian veterinary journal·2009
Same author

The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study.

Diabetologia·2008

Prostate-specific antigen (PSA) shows clinical value in detecting prostate cancer. A 10 ng/ml cutoff is recommended over 2.5 ng/ml for improved specificity and monitoring tumor growth.

Area of Science:

  • Uro-oncology
  • Clinical chemistry

Background:

  • Prostate-specific antigen (PSA) is a biomarker used for prostate cancer detection and monitoring.
  • Established cutoff values for PSA testing, like 2.5 ng/ml, have limitations in clinical practice.

Observation:

  • Analysis of sera from patients with prostatic carcinoma, benign prostatic hypertrophy (BPH), and other urological diseases.
  • PSA values ranged from 0.1 to 1,828.9 ng/ml, with 51% around 2.5 ng/ml and 76.8% around 10 ng/ml.

Findings:

  • The commercial cutoff of 2.5 ng/ml resulted in 61% false positives in BPH patients, indicating low specificity.
  • Using a 10 ng/ml cutoff reduced false negatives in prostate cancer patients to 14.6% compared to 9.75% at 2.5 ng/ml.
  • PSA levels correlated with disease stage and showed a decline after therapeutic interventions.

Related Experiment Videos

Implications:

  • A 10 ng/ml cutoff for PSA may offer a more clinically useful balance between sensitivity and specificity for prostate cancer detection.
  • PSA serves as a valuable adjuvant marker for monitoring tumor growth and treatment response in patients with prostate cancer.